For Patients

Multifocal motor neuropathy (MMN)

Multifocal motor neuropathy (MMN) is a rare, progressive, autoimmune disease of the nerves of the muscles. MMN usually develops slowly, resulting in asymmetrical weakness of the limbs, usually without numbness, tingling, or pain. Patients with MMN can also experience fasciculations (small, involuntary muscle twitches under the skin). MMN is not fatal and does not diminish life expectancy, but it is a chronic condition without remission. Treatment can limit the progression and improve function, however. Once treated, many patients only experience mild symptoms over prolonged periods. Nevertheless, MMN can lead to significant disability, with loss of function in hands affecting the ability to work and perform everyday tasks, and foot drop making it hard to stand and walk. Some patients progress to the point of using mobility assistance devices such as canes, splints, and walkers.

Treatments

  • Cyclophosphamide
  • Immune Globulin Therapy
  • Rituxan (rituximab)

More Information

Please visit the GBS/CIDP Foundation International at https://www.gbs-cidp.org/

Please visit the Neuropathy Action Foundation at http://www.neuropathyaction.org/

Products We Offer

Immune Globulin Therapy

Corticosteroids

Contact CSI Pharmacy for more information on Corticosteroids.

Immune Globulin Therapy

Immune globulin is made from pooled plasma collected from thousands of donors and treated to remove contaminants to ensure product safety and integrity. Containing antibodies against a broad spectrum of bacteria and viruses, IVIG is administered intravenously and is used primarily to treat three categories of illnesses: primary immune deficiency diseases, autoimmune diseases and certain neurological disorders.

  • Bivigam
    ADMA Biologics
  • Gammagard S/D
    Takeda
  • Gammagard Liquid
    Takeda
  • Gammaked
    Kedrion
  • Gamunex-C
    Grifols
  • Octagam 5%
    Octapharma
  • Octagam 10%
    Octapharma
  • Privigen
    CSL Behring
  • Panzyga
    Pfizer

Immune globulin is made from pooled plasma collected from thousands of donors and treated to remove contaminants to ensure product safety and integrity. Containing antibodies against a broad spectrum of bacteria and viruses, SCIG is administered subcutaneously and is approved to treat primary immune deficiencies and chronic inflammatory demyelinating polyneuropathy. It is also in clinical trials for autoimmune diseases.

  • Cutaquig
    Pfizer
  • Cuvitru
    Takeda
  • Gammagard Liquid
    Takeda
  • Gammaked
    Kedrion
  • Gamunex-C
    Grifols
  • Hizentra
    CSL Behring
  • HyQvia
    Takeda
  • Xembify
    Grifols